Literature DB >> 7671630

Intraocular pressure response to intravitreal injection of endothelin-1 and the mediatory role of ETA receptor, ETB receptor, and cyclooxygenase products in rabbits.

K Sugiyama1, M S Haque, K Okada, T Taniguchi, Y Kitazawa.   

Abstract

Endothelin-1 (ET-1) affects intraocular pressure (IOP) in rabbits. First, we studied IOP responses to the intravitreal injection of various doses of ET-1 ranging from 5 ng to 5 micrograms in unanesthetized rabbits, and observed a transient rise in IOP, from 0.5 to 2 h in duration, invariably followed by a prolonged IOP reduction, lasting for more than 72 h in rabbits treated with 0.5 microgram and 5 micrograms of ET-1. ET-1 (0.05 microgram and 0.15 microgram) resulted in a prolonged IOP reduction without an early IOP rise. Both IOP rise and reduction were significantly related to the dose of ET-1. A masked, randomized, study revealed that the intraperitoneal administration of indomethacin (50 mg/kg) prior to ET-1 injection significantly reduced the ocular hypertensive response, but not th ocular hypotensive response, to ET-1. The ETA receptor selective antagonist, 97-139 (155 micrograms) had no effect on IOP when used alone. However, when used in combination with 0.5 microgram of ET-1, 97-139 significantly inhibited both the IOP rise (0.5-2 h) and reduction (8-96 h) caused by ET-1. The ETB receptor selective agonist, sarafotoxin S6c (0.5 microgram), caused a sustained IOP reduction of 2 to 96 h in duration without the initial IOP rise. We also determined the concentration of prostaglandin (PG) E2 in the aqueous humor using radioimmunoassay techniques on samples obtained at 1 and 24 h after ET-1 injection, and examined the effects of pretreatment with indomethacin or 97-139 on PGE2 concentration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671630     DOI: 10.3109/02713689509003759

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  7 in total

Review 1.  Endothelin antagonism as an active principle for glaucoma therapy.

Authors:  Rita Rosenthal; Michael Fromm
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Pharmacological regulation of outflow resistance distal to Schlemm's canal.

Authors:  Fiona McDonnell; W Michael Dismuke; Darryl R Overby; W Daniel Stamer
Journal:  Am J Physiol Cell Physiol       Date:  2018-04-06       Impact factor: 4.249

Review 3.  Eyeing endothelins: a cellular perspective.

Authors:  Ganesh Prasanna; Santosh Narayan; Raghu R Krishnamoorthy; Thomas Yorio
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

4.  Endothelin-1 concentration is increased in the aqueous humour of patients with exfoliation syndrome.

Authors:  G G Koliakos; A G P Konstas; U Schlötzer-Schrehardt; G Hollo; D Mitova; D Kovatchev; S Maloutas; N Georgiadis
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

5.  Effect of Dual Endothelin Receptor Antagonist on a Retinal Degeneration Animal Model by Regulating Choroidal Microvascular Morphology.

Authors:  Xiaowei Zhu; Xuming Lin; Ying Xu; Naiyang Li; Qing Zhou; Xiaowei Sun; Yuanbin Li
Journal:  J Ophthalmol       Date:  2021-11-19       Impact factor: 1.909

6.  Systemic endothelial function in primary open-angle glaucoma.

Authors:  Mustafa Atas; Hasan Basri Arifoglu; Arzu Seyhan Karatepe Hashas; Bahadır Sarli; Suleyman Demircan; Ayse Ozkose; Altan Goktas
Journal:  J Ophthalmol       Date:  2014-06-18       Impact factor: 1.909

7.  Retrobulbar hemodynamics and aqueous humor levels of endothelin-1 in exfoliation syndrome and exfoliation glaucoma.

Authors:  Stavroula C Koukoula; Andreas Katsanos; Ioannis K Tentes; Georgios Labiris; Vassilios P Kozobolis
Journal:  Clin Ophthalmol       Date:  2018-07-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.